Press release
Chronic Inflammatory Demyelinating Polyneuropathy Market Trends Highlight Clinical Trials, FDA Activity, and Global Market Expansion
Chronic Inflammatory Demyelinating Polyneuropathy
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is led by major players such as Grifols, CSL Behring, Octapharma, Baxter, and Kedrion S.p.A., who dominate the immunoglobulin therapy segment. Companies like Bio Products Laboratory Ltd, Shire, and Momenta Pharmaceuticals are expanding their neurology pipelines through innovation and partnerships. Mitsubishi Tanabe Pharma, Teijin Pharma, and Pfizer Inc. are advancing biologic and immunomodulatory treatments.
Download your exclusive sample report today: https://www.datamintelligence.com/download-sample/chronic-inflammatory-demyelinating-polyneuropathy-market?jd
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market M&A & Strategic Collaborations
1. argenx & Zai Lab partnership advancing Vyvgart Hytrulo launch in China
In May 2025, argenx SE and Zai Lab extended their collaboration to support the introduction of Vyvgart Hytrulo, the first subcutaneous FcRn blocker approved for CIDP, into Chinese clinics, aiming to improve treatment convenience and patient access in Greater China.
2. Takeda's GAMMAGARD LIQUID FDA label expansion
In January 2024, Takeda secured FDA approval for GAMMAGARD LIQUID as an IVIG therapy for adult CIDP, with expanded use gaining traction in early 2025 across North America and Europe under national immunoglobulin supply networks.
3. Argenx's Vyvgart Hytrulo boosts clinic readiness
In June 2025, ar¬genx's subcutaneous treatment received momentum in North America following strong real-world outcomes in the ADHERE trial, facilitating new partnerships with infusion centers and health providers for broader rollout.
As per our analysis, these developments underscore the CIDP market's emphasis on therapeutic innovation, label expansions, and cross-border market strategies.
Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/chronic-inflammatory-demyelinating-polyneuropathy-market?jd
Key Growth Drivers & Emerging Opportunities in the CIDP Market
• The rising global prevalence of autoimmune neuropathies is increasing demand for long-term CIDP management solutions.
• Advancements in immunoglobulin and FcRn-targeted therapies (e.g., Vyvgart Hytrulo) are reshaping treatment approaches.
• Improved diagnostic capabilities and earlier disease detection are expanding the eligible patient population.
• Ongoing clinical trials in monoclonal antibodies, subcutaneous therapies, and corticosteroid alternatives are opening new market opportunities.
• Strategic partnerships in emerging markets are enhancing access to CIDP therapies through localized production and distribution.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=chronic-inflammatory-demyelinating-polyneuropathy-market?jd
Regional Market Drivers for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
North America leads the market due to strong reimbursement systems, high awareness of rare neurological disorders, and early adoption of IVIG and emerging biologics.
Europe benefits from government-funded treatment programs, centralized immunoglobulin supply chains, and robust rare disease surveillance systems.
Asia-Pacific is experiencing rapid growth with increased healthcare access, improving neurology diagnostics, and rising investments in autoimmune disorder research.
Latin America is driven by improving healthcare infrastructure and growing availability of immunoglobulin therapies through international health partnerships.
Middle East & Africa show steady progress due to expanding specialist care facilities and global aid programs supporting rare disease treatment access.
Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Inflammatory Demyelinating Polyneuropathy Market Trends Highlight Clinical Trials, FDA Activity, and Global Market Expansion here
News-ID: 4104799 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Seeds Market Outlook: Growth Drivers, Key Players & Future Trends
Market Size and Growth:
The Global Seeds Market reached USD 57.5 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 95.1 billion by 2031. The market is expected to exhibit a CAGR of 6.5% during the forecast period 2024-2031, according to the DataM Intelligence report.
Download Exclusive Sample Report: https://www.datamintelligence.com/download-sample/seeds-market?juli
Industry Recent Developments: United States
✅ In the United States, seed companies are actively rolling out next‐generation traited…
Vaginal Health Probiotic Market to Reach $1.19 Billion by 2032 | Top Companies a …
According to DataM Intelligence, the vaginal health probiotic supplements market was valued at US$ 665.12 million in 2024 and is projected to reach US$ 1,195.08 million by 2032, growing at a CAGR of 7.6% from 2025 to 2032. Key factors driving this growth include the increasing incidence of bacterial vaginosis (BV), recurrent urinary tract infections (UTIs), and vaginal yeast infections, as well as heightened interest in preventive healthcare. Among all…
Cathode Materials Market to reach USD 129.1 Billion by 2032, driven by EVs, ESS, …
According to DataM Intelligence, the cathode materials market reached USD 47.2 billion in 2024 and is projected to grow to USD 129.1 billion by 2032, registering a CAGR of 13.4% during 2025-2032. The lithium-ion battery segment holds the largest market share, accounting for about 49.2% in 2024, owing to its superior energy density and versatility. Regionally, Asia-Pacific dominates the market with around 32.7% of the total share, supported by China's…
Protein Expression & Purification Services Market Set to Reach $8.95 Billion by …
The global protein expression & purification services market reached US$ 3.96 billion in 2023, with a rise to US$ 4.30 billion in 2024, and is expected to reach US$ 8.95 billion by 2033, growing at a CAGR of 9.6% during the forecast period 2025-2033.
DataM Intelligence has published a new research report on "Protein Expression & Purification Services Market Size 2025". The report explores comprehensive and insightful Information about various key…
More Releases for CIDP
CIDP Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landsca …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Inflammatory Demyelinating Polyneuropathy pipeline constitutes 2+ key companies continuously working towards developing 4+ Chronic Inflammatory Demyelinating Polyneuropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth, Trends, …
Introduction
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the arms and legs due to damage to the myelin sheath surrounding peripheral nerves. Though uncommon, CIDP significantly affects patient quality of life and requires long-term management, often involving immunotherapy, corticosteroids, and plasma exchange.
Over the past decade, improved diagnostic capabilities, greater awareness of rare neurological diseases, and advancements in immunoglobulin therapies…
CIDP Market Emerging Trends and Growth Prospects 2034
Introduction
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare, immune-mediated neuropathy characterized by progressive or relapsing weakness, sensory loss, and impaired reflexes due to demyelination of peripheral nerves. Unlike acute Guillain-Barré syndrome, CIDP evolves over at least eight weeks and, without timely treatment, can lead to significant long-term disability. The condition encompasses typical CIDP and several clinical variants (e.g., MADSAM/Lewis-Sumner, DADS, pure motor, pure sensory), each with nuanced diagnostic and therapeutic…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Market Insights and Co …
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market sector is undergoing significant transformation, with substantial growth and technological advancements expected by 2031. According to a new in-depth market research report, the sector is poised for expansion, driven by various factors such as market size, share, and emerging trends.
This comprehensive report provides key insights into the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market, exploring critical market segmentation and definitions. It highlights the essential…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market 2024-2 …
Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market is an uncommon autoimmune disorder affecting the peripheral nervous system. It manifests through the progressive weakening of muscles and the loss of sensation in extremities. The CIDP treatment market has shown consistent growth and is poised for significant expansion in the forthcoming years. In this comprehensive blog post, we will delve into the current scenario, regulatory framework, market dynamics, supplier landscape, drug distribution model,…
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Insights …
The market for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was valued USD 968 Million in 2017 which is anticipated to reach USD 2,020.6 Million by 2030.
The total number of CIDP patients in the 7MM is projected to reach 55,113 by 2030 from 46,027 in 2019. The U.S. has the highest incidences of CIDP in the 7MM. In 2019, as per the data studied by Report Ocean, there were approximately 29,000…
